<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article86</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/JUPITER" style="display:block; margin-bottom:10px;">JUPITER Original</a></li>
<h2><strong>JUPITER</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein". The New England Journal of Medicine. 2008. 359(21):2195-2207. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does rosuvastatin treatment reduce the incidence of major cardiovascular events in men and women with normal LDL levels but elevated C-reactive protein?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Rosuvastatin significantly reduced the incidence of major cardiovascular events in apparently healthy persons with elevated high-sensitivity C-reactive protein and without hyperlipidemia.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Updated guidelines should consider rosuvastatin therapy for primary prevention in individuals with elevated CRP.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, double-blind, placebo-controlled trial<br/>
- N=17,802<br/>
- Rosuvastatin 20mg daily (n=8,901) vs. placebo (n=8,901)<br/>
- Median follow-up: 1.9 years (maximum: 5.0 years)<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Occurrence of major cardiovascular events defined as nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Men ≥50 years and women ≥60 years with no history of cardiovascular disease, LDL cholesterol &lt;130 mg/dL, high-sensitivity C-reactive protein ≥2.0 mg/L<br/>
- Exclusion Criteria: Previous use of lipid-lowering therapy, postmenopausal hormone replacement therapy, hepatic dysfunction, creatinine kinase &gt;3x upper limit, diabetes, uncontrolled hypertension, inflammatory diseases, or recent drug/alcohol abuse.<br/>
- Baseline Characteristics: Varied population including 38.2% women and 25.2% Black or Hispanic; median LDL cholesterol 108 mg/dL.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Rosuvastatin 20 mg daily or matching placebo.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: Rosuvastatin reduced the rate of the primary endpoint by 44% compared to placebo (HR 0.56; 95% CI 0.46-0.69; P&lt;0.00001).<br/>
- Secondary Outcomes: Significant reductions in the rates of myocardial infarction, stroke, arterial revascularization, and unstable angina. Modest but significant reduction in all-cause mortality with rosuvastatin.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Early termination of the trial might have underestimated the rates of adverse events.<br/>
- Increased rate of physician-reported diabetes in the rosuvastatin group.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
